Skip to main content
HR 1424 114th Congress House Environmental Protection Consumer affairs Drug safety, medical device, and laboratory regulation Hazardous wastes and toxic substances Health promotion and preventive care Infectious and parasitic diseases Marketing and advertising Medical research Metals Pest management Retail and wholesale trades

Infection Reduction Labeling Act

Introduced: June 9, 2015 Introduced by: Latta, Robert E. Republican · Ohio See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 114th Congress ended
It never became law before the 114th Congress (2015–2016) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 8, 2015
Referred to the Subcommittee on Biotechnology, Horticulture, and Research.
Mar 20, 2015
Referred to the Subcommittee on Health.
Mar 18, 2015
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Agriculture, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Mar 18, 2015
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Infection Reduction Labeling Act

This bill amends the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) to authorize solid antimicrobial copper alloys, and products made from such alloys, to be marketed, distributed, or sold with labels about their infection reduction and control efficacy if the antimicrobial claims made on the label are consistent with the results of federally-funded clinical trials finding: (1) greater than 25% reductions in infection rate or 50% reductions in microbial burden, or (2) statistically significant reductions in infection rate or microbial burden.

Requirements to submit or review efficacy data related to the antimicrobial claims are waived for these alloys if the claims are consistent with the results of the trials.

An alternative process to modify the labeling of an alloy may be used in lieu of the current process.

This bill amends the Federal Food, Drug, and Cosmetic Act to exclude a product that is made from the alloy and has the antimicrobial labeling from regulation and treatment as a drug or device.

What's happening now April 8, 2015

Referred to the Subcommittee on Biotechnology, Horticulture, and Research.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
 Cosponsors 7
All 7 Democratic 1 Republican 3
D
Boyle, Brendan F.
Pennsylvania · Jul 29, 2015
 R
Joyce, David P.
Ohio · Jul 29, 2015
Blum, Rod
· Jun 9, 2015
 R
Crawford, Eric A. "Rick"
Arkansas · Jun 9, 2015
Shuster, Bill
· Jun 1, 2015
 R
Bost, Mike
Illinois · May 18, 2015
Murphy, Tim
· Mar 18, 2015
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 1424: Infection Reduction Labeling Act. 114th Congress. Open America. https://openamerica.io/bill/114-HR-1424/
MLA
"H.R. 1424: Infection Reduction Labeling Act." 114th Congress, 2026, Open America, https://openamerica.io/bill/114-HR-1424/.
Bluebook (legal)
H.R. 1424, 114th Cong. (2026), https://openamerica.io/bill/114-HR-1424/.
Markdown link
[H.R. 1424: Infection Reduction Labeling Act](https://openamerica.io/bill/114-HR-1424/)
Report a problem